Literature DB >> 22172337

Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells.

Giovanna Danza1, Claudia Di Serio, Fabiana Rosati, Giuseppe Lonetto, Niccolò Sturli, Doreen Kacer, Antonio Pennella, Giuseppina Ventimiglia, Riccardo Barucci, Annamaria Piscazzi, Igor Prudovsky, Matteo Landriscina, Niccolò Marchionni, Francesca Tarantini.   

Abstract

UNLABELLED: Prostate carcinoma is among the most common causes of cancer-related death in men, representing 15% of all male malignancies in developed countries. Neuroendocrine differentiation (NED) has been associated with tumor progression, poor prognosis, and with the androgen-independent status. Currently, no successful therapy exists for advanced, castration-resistant disease. Because hypoxia has been linked to prostate cancer progression and unfavorable outcome, we sought to determine whether hypoxia would impact the degree of neuroendocrine differentiation of prostate cancer cells in vitro.
RESULTS: Exposure of LNCaP cells to low oxygen tension induced a neuroendocrine phenotype, associated with an increased expression of the transcription factor neurogenin3 and neuroendocrine markers, such as neuron-specific enolase, chromogranin A, and β3-tubulin. Moreover, hypoxia triggered a significant decrease of Notch 1 and Notch 2 mRNA and protein expression, with subsequent downregulation of Notch-mediated signaling, as shown by reduced levels of the Notch target genes, Hes1 and Hey1. NED was promoted by attenuation of Hes1 transcription, as cells expressing a dominant-negative form of Hes1 displayed increased levels of neuroendocrine markers under normoxic conditions. Although hypoxia downregulated Notch 1 and Notch 2 mRNA transcription and receptor activation also in the androgen-independent cell lines, PC-3 and Du145, it did not change the extent of NED in these cultures, suggesting that androgen sensitivity may be required for transdifferentiation to occur.
CONCLUSIONS: Hypoxia induces NED of LNCaP cells in vitro, which seems to be driven by the inhibition of Notch signaling with subsequent downregulation of Hes1 transcription. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22172337      PMCID: PMC3433043          DOI: 10.1158/1541-7786.MCR-11-0296

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  53 in total

1.  HES-1 inhibits 17beta-estradiol and heregulin-beta1-mediated upregulation of E2F-1.

Authors:  Johan Hartman; Patrick Müller; James S Foster; Jay Wimalasena; Jan-Ake Gustafsson; Anders Ström
Journal:  Oncogene       Date:  2004-11-18       Impact factor: 9.867

2.  Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation.

Authors:  Xi-De Wang; Ching Ching Leow; Jiping Zha; Zhijun Tang; Zora Modrusan; Freddy Radtke; Michel Aguet; Frederic J de Sauvage; Wei-Qiang Gao
Journal:  Dev Biol       Date:  2005-12-15       Impact factor: 3.582

Review 3.  Management of the spectrum of hormone refractory prostate cancer.

Authors:  Noel W Clarke
Journal:  Eur Urol       Date:  2006-06-02       Impact factor: 20.096

4.  Effect of the hsp90 inhibitor geldanamycin on androgen response of prostate cancer under hypoxic conditions.

Authors:  Yasutomo Suzuki; Yukihiro Kondo; Shuntaro Hara; Ryouji Kimata; Taiji Nishimura
Journal:  Int J Urol       Date:  2010-03       Impact factor: 3.369

5.  Notch activation suppresses fibroblast growth factor-dependent cellular transformation.

Authors:  Deena Small; Dmitry Kovalenko; Raffaella Soldi; Anna Mandinova; Vihren Kolev; Radiana Trifonova; Cinzia Bagala; Doreen Kacer; Chiara Battelli; Lucy Liaw; Igor Prudovsky; Thomas Maciag
Journal:  J Biol Chem       Date:  2003-02-21       Impact factor: 5.157

6.  Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients.

Authors:  Marko Tarle; M Zaky Ahel; Ksenija Kovacić
Journal:  Anticancer Res       Date:  2002 Jul-Aug       Impact factor: 2.480

7.  Neuroendocrine differentiation is involved in chemoresistance induced by EGF in prostate cancer cells.

Authors:  Yuan Li; He Qun Chen; Min Feng Chen; Huai Zheng Liu; Yuan Qing Dai; Hui Lv; Xiong Bing Zu; Lin Qi
Journal:  Life Sci       Date:  2009-04-06       Impact factor: 5.037

Review 8.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

Authors:  Todd M Morgan; Theodore D Koreckij; Eva Corey
Journal:  Curr Cancer Drug Targets       Date:  2009-03       Impact factor: 3.428

9.  NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.

Authors:  Ren Jie Jin; Yongqing Wang; Naoya Masumori; Kenichiro Ishii; Taiji Tsukamoto; Scott B Shappell; Simon W Hayward; Susan Kasper; Robert J Matusik
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

Review 10.  Rational targeting of Notch signaling in cancer.

Authors:  P Rizzo; C Osipo; K Foreman; T Golde; B Osborne; L Miele
Journal:  Oncogene       Date:  2008-09-01       Impact factor: 9.867

View more
  37 in total

Review 1.  Hypoxia, notch signalling, and prostate cancer.

Authors:  Laure Marignol; Karla Rivera-Figueroa; Thomas Lynch; Donal Hollywood
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

Review 2.  Hes1: a key role in stemness, metastasis and multidrug resistance.

Authors:  Zi-Hao Liu; Xiao-Meng Dai; Bin Du
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 3.  Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.

Authors:  Loredana Puca; Panagiotis J Vlachostergios; Himisha Beltran
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

4.  MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines.

Authors:  Pasqualino de Antonellis; Lucia Liguori; Annarita Falanga; Marianeve Carotenuto; Veronica Ferrucci; Immacolata Andolfo; Federica Marinaro; Immacolata Scognamiglio; Antonella Virgilio; Giuseppe De Rosa; Aldo Galeone; Stefania Galdiero; Massimo Zollo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-01-26       Impact factor: 3.000

Review 5.  The biology and clinical implications of prostate cancer dormancy and metastasis.

Authors:  Colm Morrissey; Robert L Vessella; Paul H Lange; Hung-Ming Lam
Journal:  J Mol Med (Berl)       Date:  2015-10-21       Impact factor: 4.599

Review 6.  RANK-mediated signaling network and cancer metastasis.

Authors:  Gina Chia-Yi Chu; Leland W K Chung
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

Review 7.  NUMB inhibition of NOTCH signalling as a therapeutic target in prostate cancer.

Authors:  Angela N Flores; Niamh McDermott; Armelle Meunier; Laure Marignol
Journal:  Nat Rev Urol       Date:  2014-08-19       Impact factor: 14.432

Review 8.  Notch signaling in the prostate: critical roles during development and in the hallmarks of prostate cancer biology.

Authors:  Gang Deng; Libin Ma; Qi Meng; Xiang Ju; Kang Jiang; Peiwu Jiang; Zhijian Yu
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-04       Impact factor: 4.553

9.  Epigenetic modification of TLE1 induce abnormal differentiation in diabetic mice intestinal epithelium.

Authors:  Ji-Hao Xu; Guang-Cheng Chen; Can-Ze Huang; Di Cheng; Ting-Feng Wu; Si-Yi Wang; Jie-Yao Li; Tao Yu; Qi-Kui Chen
Journal:  Mol Cell Biochem       Date:  2017-07-25       Impact factor: 3.396

10.  Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model.

Authors:  Oh-Joon Kwon; Li Zhang; Jianghua Wang; Qingtai Su; Qin Feng; Xiang H F Zhang; Sendurai A Mani; Robia Paulter; Chad J Creighton; Michael M Ittmann; Li Xin
Journal:  J Clin Invest       Date:  2016-06-13       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.